In the clinical treatment of advanced NSCLC, ICI targeting PD1/PD‐L1 has made rapid progress,17 PD1/PD‐L1 inhibitor monotherapy or combination therapy with chemotherapy/antiangiogenic therapy has become one of the main treatment especially for NSCLC patients without the presence of driver gene mutation.18 The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.